Clinical Trials | AdventHealth Research Institute

Showing 13 - 13 of 13 clinical trials matching your search

NCT06253130

EIK1003-001 (IMP1734-101): A first-in-human, Phase 1/2, open-label, multi-center, dose escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors

This study is not currently enrolling.

Research Area: Cancer Research

Research Location: Celebration, Florida

The study treatment is IMP1734, which is an experimental drug which means that regulatory authorities have allowed the study to be tested in this clinical trial for its potential to treat cancers in...